BioStem Technologies, Inc. — Cyborg Score 7/10

Strong
Pharmaceuticals

Strategic Profile

In January 2026, BioStem acquired the Surgical and Wound Care Business of BioTissue Holdings Inc. for $40 million, with the transaction expected to be accretive to BioStem's growth, EBITDA and profitability in 2026. In April 2026, the company presented at the 25th Annual Needham Virtual Healthcare Conference, highlighting its continued progress in regenerative medicine and expanding portfolio of advanced perinatal tissue allografts.

Cyborg Score Rationale

BioStem demonstrates solid execution with a meaningful acquisition expanding its product portfolio, recent analyst coverage with Buy ratings, and direct market presence in high-value wound care applications. However, OTC trading status and modest scale limit institutional access.

Top Insights

  • Completed transformational acquisition of BioTissue's Surgical and Wound Care Business (January 2026) with $29M trailing revenue, positioning company for 2026 profitability
  • Proprietary BioRetain processing technology differentiates perinatal tissue allografts in competitive wound care market
  • Product portfolio includes VENDAJE, VENDAJE AC, VENDAJE OPTIC, and American Amnion targeting multiple clinical applications
  • Active investor relations strategy with healthcare conference presentations and analyst engagement (April 2026 Needham presentation)

Named Competitors

  • BioTissue Holdings — Surgical and wound care biologics (now part of BioStem)
  • Organogenesis Holdings — Advanced wound care and regenerative medicine products
  • Mimedx — Placental tissue allografts for wound and surgical care

Recent Developments

  • (January 2026) Acquired Surgical and Wound Care Business of BioTissue Holdings Inc. for $40M
  • (April 2026) Presented at 25th Annual Needham Virtual Healthcare Conference highlighting regenerative medicine portfolio
  • (April 2026) Participated in SAWC Spring wound care conference
  • (Q1 2026) Released financial results for period ended March 31, 2026

Open the full interactive BioStem Technologies, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →